EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS
EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS
复制标题
DOI：
10.1056/nejm198405243102104
复制
发表时间：
1984-01-01
影响因子：
158.5
通讯作者：
ALEXANIAN, R
中科院分区：
文献类型：
--
作者：
BARLOGIE, B;SMITH, L;ALEXANIAN, R
29 名晚期难治性多发性骨髓瘤患者接受间歇性高剂量地塞米松联合 4 天长春新碱和阿霉素输注治疗。在 20 名对烷化剂具有耐药性的患者中，有 14 名患者的肿瘤质量快速且显着减少 (> 75%)，在 9 名对阿霉素具有额外耐药性的患者中，有 3 名患者的肿瘤质量迅速且显着减少 (> 75%)，这一结果远远优于之前对类似患者进行的试验。在有反应的患者中，缓解质量非常好；生存期明显长于无反应患者。
Twenty-nine paitents with advanced refractory multiple myeloma were treated with intermittent high-dose dexamethasone in combination with 4-day infusions of vincristine and doxorubicin. Rapid and marked tumor-mass reduction (> 75%) was noted in 14 of 20 patients whose disease was resistant to alkylating agents and in 3 of 9 patients with additional resistance to doxorubicin, a result far superior to those in previous trials with similar patients. In responsive patients, remissions were of excellent quality; survival was significantly longer than in unresponsive patients.